RxDoctor Payments DataLook up a doctor →

David Miller, MD

Pulmonary Disease · Decatur, GANPI 1265430797

Payments from drug & device makers

$205,923in general payments, 2019–2025

Across 1,451 payments — averaging $141.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Actelion Pharmaceuticals US, Inc.$95K
  • AstraZeneca$54K
  • Boehringer Ingelheim$11K
  • Mylan Specialty L.p.$10K
  • Amgen$5K
  • Electromed, Inc.$4K
  • plus $27K from 46 others

What the payments were for

  • Consulting fees$22,06411%
  • Speaking & faculty fees$129,56863%
  • Travel & lodging$10,6135%
  • Food & beverage$42,68521%
  • Education$9920%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$205,923 in reported general payments places this provider in the 90th percentile of 365 pulmonary disease providers in Georgia.

See all pulmonary disease providers in Georgia

Medicare billing

Part B allowed, 2024
$110,826
Medicare patients
244
Services billed
1,236

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate66$873,788
OpsumitMacitentan55$691,659
Trelegy ElliptaFluticasone/Umeclidin/Vilanter825$645,326
UptraviSelexipag20$519,298
AdempasRiociguat36$481,813
Breztri AerosphereBudesonide/Glycopyr/Formoterol235$163,176
Breo ElliptaFluticasone/Vilanterol125$74,566
FasenraBenralizumab13$73,641
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr70$37,355
Orenitram ErTreprostinil Diolamine18$22,984
Stiolto RespimatTiotropium Br/Olodaterol Hcl34$18,650
Spiriva RespimatTiotropium Bromide16$12,568
Albuterol Sulfate HfaAlbuterol Sulfate383$9,981
Arnuity ElliptaFluticasone Furoate40$9,773
AirsupraAlbuterol Sulfate/Budesonide19$8,926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi$95,476$1,210,95875 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$10,502$905,007116 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta$2,953$767,0201,060 claims
BayerAdempas$4,212$481,81336 claims
AstraZenecaBreztri Aerosphere, Fasenra, Airsupra, Symbicort, Daliresp$53,979$260,251310 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 365 pulmonary disease providers in Georgia.

Other pulmonary disease in Decatur

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →